arrow
V

Virginia F. Borges

university of colorado
H-index:60
Citation Count:1.3万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial

POSITIVE试验(女性内分泌敏感性乳腺癌中断治疗的妊娠结局与安全性)最新结果

2026-05-280
PRE
Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort

胚系BRCA1/2携带者两组匹配队列的研究结果与治疗模式

2026-05-250
OA
Psychosocial support utilization among breast cancer patients experiencing reproductive concerns: A cross-sectional cohort study

乳腺癌患者中存在生殖问题的患者的心理社会支持利用情况:一项横断面队列研究

2025-12-010
PRE
ACR Appropriateness Criteria® Breast Imaging During Pregnancy

ACR Appropriateness Criteria®孕期乳腺影像检查

2025-11-030
PRE
Fertility preservation and fertility treatment use in young breast cancer survivors reporting a live birth

乳腺癌幸存者生育力保存及生育治疗的使用情况报告:活产出生

2025-09-270
PRE
Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]

勘误:“Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]

2025-09-220
PREAI
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

POSITIVE试验中,预测乳腺癌患者为尝试生育而中断辅助内分泌治疗时生育力的激素因素

2025-07-260
OAAI
Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer

HER2酪氨酸激酶抑制剂序贯疗法在HER2阳性转移性乳腺癌患者中的应用

2025-06-110
OAAI
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy

二线化疗进展后的转移性三阴性乳腺癌患者中Imprime与Pembrolizumab免疫疗法的二期临床试验

2025-05-080
PRE
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes
2025-01-240
OAAI
A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health (Nov, 10.1007/s10549-024-07522-4, 2024)
2024-12-200
OAAI
A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health
2024-11-122
OAAI
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer
2024-10-061
OAAI
Prognostic and therapeutic implications of tumor-restrictive type III collagen in the breast cancer microenvironment
2024-10-021
OAAI
Breastfeeding experiences among young breast cancer survivors: A survey study
CANCER
IF5.1
2024-09-290
PRE
Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy
2024-08-012
OA
Association of cancer treatment with excess heart age among five-year young breast cancer survivors
2024-07-150
OA
Second primary non-breast cancers in young breast cancer survivors
2024-06-101
PRE
Five-year quality of life (QOL) trajectories among young breast cancer (BC) survivors
2024-05-020
PRE
Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
2024-05-020
PRE